SCHEMBL3565052

SCHEMBL3565052

CCOC(=O)c1ccc(CN2CCN(CCO)CC2)c(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
KIT P10721 2/20 0.47
NR1H2 P55055 1/20 0.46
ABL1 P00519 5/20 0.46
ABL2 P42684 1/20 0.46
BRAF P15056 3/20 0.46
JAK2 O60674 1/20 0.46
EGFR P00533 1/20 0.46
RET P07949 1/20 0.46
PDGFRB P09619 1/20 0.46
FGFR1 P11362 1/20 0.46
SRC P12931 1/20 0.46
PDGFRA P16234 1/20 0.46
FLT1 P17948 1/20 0.46
FGFR2 P21802 1/20 0.46
FGFR4 P22455 1/20 0.46
FGFR3 P22607 1/20 0.46
JAK1 P23458 1/20 0.46
CCNE1 P24864 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3568167 0.91 ALDH1A1 (0.47) ALDH1A1KDM4EKITNR1H2ABL1
SCHEMBL374710 0.91 NR1H2 (0.57) ALDH1A1KDM4EKITNR1H2ABL1
SCHEMBL28024000 0.90 KDM4E (0.50) ALDH1A1KDM4EKITABL1ABL2
SCHEMBL20196012 0.87 DDR1 (0.51) ALDH1A1KDM4EKITNR1H2DDR1
SCHEMBL16528525 0.83 ALDH1A1 (0.47) ALDH1A1KDM4EKITDDR1TDP1
SCHEMBL16380771 0.82 NR1H2 (0.51) ALDH1A1KDM4EKITNR1H2ABL1
SCHEMBL10973660 0.80 CA12 (0.51) ALDH1A1KDM4EMAPT
SCHEMBL9610933 0.80 NR1H2 (0.53) ALDH1A1KDM4EKITNR1H2ABL1
SCHEMBL14317630 0.80 NR1H2 (0.56) ALDH1A1KDM4EKITNR1H2ABL1
SCHEMBL3942805 0.79 MAPT (0.51) ALDH1A1KDM4EABL1RETKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299358-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2018-03-28 EP disclosed
EP-1702917-B1 AMIDE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2017-08-02 EP disclosed
CN-101456841-B Amide derivative and medicine NIPPON SHINYAKU CO LTD 2012-01-25 CN disclosed
US-7728131-B2 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia NIPPON SHINYAKU CO., LTD. (JP) 2010-06-01 US disclosed
CN-100526298-C Amide derivative and pharmaceutical NIPPON SHINYAKU CO LTD (JP) 2009-08-12 CN disclosed
CN-101456841-A Amide derivative and medicine NIPPON SHINYAKU CO LTD (JP) 2009-06-17 CN disclosed
US-20080293940-A1 Amide Derivative and Medicine NIPPON SHINYAKU CO., LTD. (JP) 2008-11-27 US disclosed
CN-1898208-A Amide derivative and pharmaceutical NIPPON SHINYAKU CO LTD (JP) 2007-01-17 CN disclosed
EP-1702917-A1 AMIDE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293940-A1 Amide Derivative and Medicine ABL2, ABL1, BCR ALDH1A1 518/4885KDM4E 1978/4885KIT 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.